Short Interest in Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Drops By 43.8%

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) was the target of a significant drop in short interest in the month of July. As of July 31st, there was short interest totaling 178,300 shares, adropof43.8% from the July 15th total of 317,500 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is currently 1,783.0 days. Currently,0.1% of the company's stock are sold short. Currently,0.1% of the company's stock are sold short. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is currently 1,783.0 days.

Swedish Orphan Biovitrum Price Performance

OTCMKTS:BIOVF remained flat at $28.97 during mid-day trading on Wednesday. The company has a market capitalization of $10.31 billion, a PE ratio of 24.34 and a beta of 0.46. The firm has a 50 day moving average of $29.63 and a two-hundred day moving average of $29.53. The company has a current ratio of 1.00, a quick ratio of 0.66 and a debt-to-equity ratio of 0.22. Swedish Orphan Biovitrum has a 12-month low of $25.7957 and a 12-month high of $32.25.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.06. Swedish Orphan Biovitrum had a net margin of 16.05% and a return on equity of 11.67%. The company had revenue of $649.61 million during the quarter, compared to analysts' expectations of $644.68 million.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.